CYMD
MCID: MCL027
MIFTS: 52

Macular Dystrophy, Dominant Cystoid (CYMD)

Categories: Eye diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Macular Dystrophy, Dominant Cystoid

MalaCards integrated aliases for Macular Dystrophy, Dominant Cystoid:

Name: Macular Dystrophy, Dominant Cystoid 57 13
Cystoid Macular Edema 12 6 15
Autosomal Dominant Cystoid Macular Edema 59 73
Cystoid Macular Dystrophy 57 59
Macular Edema, Cystoid 57 73
Dcmd 57 59
Cystoid Macular Dystrophy; Cymd 57
Familial Macular Edema 59
Macular Retinal Edema 73
Macular Edema 44
Cymd 57
Mddc 57

Characteristics:

Orphanet epidemiological data:

59
cystoid macular dystrophy
Inheritance: Autosomal dominant; Prevalence: <1/1000000 (Worldwide); Age of onset: Childhood;

OMIM:

57
Inheritance:
autosomal dominant (7p21-p15)


HPO:

32
macular dystrophy, dominant cystoid:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 59  
Rare eye diseases


External Ids:

OMIM 57 153880
Disease Ontology 12 DOID:4447
MeSH 44 D008269
NCIt 50 C34794
Orphanet 59 ORPHA75381
ICD10 via Orphanet 34 H35.5
MedGen 42 C0024440

Summaries for Macular Dystrophy, Dominant Cystoid

OMIM : 57 Dominant cystoid macular dystrophy (DCMD) is a progressive retinal dystrophy characterized primarily by early-onset cystoid fluid collections in the neuroretina (summary by Saksens et al., 2015). (153880)

MalaCards based summary : Macular Dystrophy, Dominant Cystoid, also known as cystoid macular edema, is related to retinal vein occlusion and macular retinal edema, and has symptoms including edema and peau d'orange. An important gene associated with Macular Dystrophy, Dominant Cystoid is CYMD (Cystoid Macular Dystrophy). The drugs Bevacizumab and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are edema and strabismus

Related Diseases for Macular Dystrophy, Dominant Cystoid

Diseases related to Macular Dystrophy, Dominant Cystoid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 176)
# Related Disease Score Top Affiliating Genes
1 retinal vein occlusion 31.3 VEGFA SERPINF1
2 macular retinal edema 31.2 VEGFA PDE6A MRAP MFRP MAK CRB1
3 central retinal vein occlusion 31.0 VEGFA SERPINF1
4 retinal detachment 30.9 VEGFA SERPINF1 CAPN5
5 microvascular complications of diabetes 5 30.6 VEGFA SERPINF1 PRKCB
6 macular holes 30.4 VEGFA SERPINF1
7 endophthalmitis 30.2 VEGFA MRAP
8 fundus dystrophy 30.1 MFRP CRB1 BEST1
9 diabetic macular edema 30.1 VEGFA SERPINF1 PRKCB
10 macular degeneration, age-related, 1 30.0 VEGFA SERPINF1 CRB1 BEST1
11 coats disease 29.9 VEGFA CRB1
12 retinal vascular disease 29.9 VEGFA SERPINF1
13 diabetic cataract 29.9 VEGFA SERPINF1
14 optic disk drusen 29.9 VEGFA MFRP CRB1
15 eales disease 29.9 VEGFA SERPINF1
16 yemenite deaf-blind hypopigmentation syndrome 29.7 VEGFA CRB1
17 retinal disease 29.2 PDE6A CRB1 BEST1
18 retinitis pigmentosa 29.0 SERPINF1 PDE6A MFRP MAK CRB1 CAPN5
19 vitreoretinopathy, neovascular inflammatory 11.7
20 vitreoretinochoroidopathy 11.4
21 perrault syndrome 1 11.1
22 cataract 11.0
23 uveitis 10.8
24 cytomegalovirus retinitis 10.5
25 microvascular complications of diabetes 1 10.5
26 microvascular complications of diabetes 2 10.5
27 gyrate atrophy of choroid and retina 10.4
28 melanoma 10.4
29 intermediate uveitis 10.4
30 acquired immunodeficiency syndrome 10.3
31 degos 'en cocarde' erythrokeratoderma 10.3
32 ischemia 10.3
33 diabetes mellitus 10.3
34 vitreous detachment 10.3
35 corneal edema 10.3
36 optic nerve disease 10.3
37 neuropathy 10.3
38 ocular hypertension 10.3
39 central serous chorioretinopathy 10.3
40 leber congenital amaurosis 4 10.2
41 retinitis 10.2
42 exudative vitreoretinopathy 1 10.2
43 birdshot chorioretinopathy 10.2
44 crohn's disease 10.2
45 leukemia 10.2
46 central retinal artery occlusion 10.2
47 poems syndrome 10.2
48 papilledema 10.2
49 retinal artery occlusion 10.2
50 retinal microaneurysm 10.1

Graphical network of the top 20 diseases related to Macular Dystrophy, Dominant Cystoid:



Diseases related to Macular Dystrophy, Dominant Cystoid

Symptoms & Phenotypes for Macular Dystrophy, Dominant Cystoid

Symptoms via clinical synopsis from OMIM:

57
Eyes:
strabismus
cystoid macular edema
whitish punctate vitreous deposits
moderate to high hyperopia
diminished visual acuity
more
Radiology:
normal electroretinogram


Clinical features from OMIM:

153880

Human phenotypes related to Macular Dystrophy, Dominant Cystoid:

32 (show all 6)
# Description HPO Frequency HPO Source Accession
1 edema 32 HP:0000969
2 strabismus 32 HP:0000486
3 macular dystrophy 32 HP:0007754
4 hypermetropia 32 HP:0000540
5 cystoid macular edema 32 HP:0011505
6 pericentral retinitis pigmentosa 32 HP:0007947

UMLS symptoms related to Macular Dystrophy, Dominant Cystoid:


edema, peau d'orange

MGI Mouse Phenotypes related to Macular Dystrophy, Dominant Cystoid:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 pigmentation MP:0001186 9.26 BEST1 CRB1 MFRP SERPINF1
2 vision/eye MP:0005391 9.1 BEST1 CRB1 MFRP PDE6A SERPINF1 VEGFA

Drugs & Therapeutics for Macular Dystrophy, Dominant Cystoid

Drugs for Macular Dystrophy, Dominant Cystoid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 362)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 124-94-7 31307
3
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 347396-82-1 459903
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-02-2 5743
5
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1177-87-3
6
Dorzolamide Approved Phase 4,Phase 2 120279-96-1 5284549 3154
7
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
8
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
9
Acetazolamide Approved, Vet_approved Phase 4,Phase 2 59-66-5 1986
10
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-24-8 5755
11
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3 302-25-0
12
Loteprednol Approved, Experimental Phase 4,Not Applicable 82034-46-6, 129260-79-3 9865442 444025
13
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3 2921-57-5
14
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 83-43-2 6741
15
Linagliptin Approved Phase 4 668270-12-0 10096344
16
Povidone-iodine Approved Phase 4,Phase 3,Not Applicable 25655-41-8
17
Diclofenac Approved, Vet_approved Phase 4,Phase 1,Not Applicable 15307-86-5 3033
18
Nepafenac Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 78281-72-8 151075
19
Methotrexate Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 59-05-2, 1959-05-2 126941
20
Temazepam Approved, Investigational Phase 4,Phase 3,Not Applicable 846-50-4 5391
21
Verteporfin Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 129497-78-5
22
Mycophenolic acid Approved Phase 4,Phase 3 24280-93-1 446541
23
Azathioprine Approved Phase 4 446-86-6 2265
24
Infliximab Approved Phase 4,Phase 3,Phase 1,Phase 2 170277-31-3
25
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
26
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 67-73-2 6215
27
Difluprednate Approved Phase 4 23674-86-4 443936
28
Fluprednisolone Approved Phase 4 53-34-9
29
Ketorolac Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 66635-83-4, 74103-06-3 3826
30
Betamethasone Approved, Vet_approved Phase 4,Phase 2,Phase 3 378-44-9 9782
31
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
32 Homatropine Approved Phase 4 87-00-3
33 tannic acid Approved Phase 4,Phase 2,Phase 3,Phase 1
34
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 94-09-7, 1994-09-7 2337
35
leucovorin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 58-05-9 6006 143
36
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
37
Glimepiride Approved Phase 4 93479-97-1 3476
38
Empagliflozin Approved Phase 4 864070-44-0
39
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
40
Travoprost Approved Phase 4 157283-68-6 5282226
41
Bimatoprost Approved, Investigational Phase 4,Phase 3,Phase 2 155206-00-1 5311027
42
Timolol Approved Phase 4,Phase 2,Not Applicable 26839-75-8 33624 5478
43
Latanoprost Approved, Investigational Phase 4,Phase 2 130209-82-4 5311221 5282380
44
Zinc Approved, Investigational Phase 4 7440-66-6
45
Insulin Glargine Approved Phase 4 160337-95-1
46
Chlorambucil Approved Phase 4 305-03-3 2708
47
Cyclophosphamide Approved, Investigational Phase 4 6055-19-2, 50-18-0 2907
48
Tacrolimus Approved, Investigational Phase 4,Phase 3 104987-11-3 445643 439492
49
Dinoprost Tromethamine Approved, Vet_approved Phase 4 38562-01-5 5282415
50
Dinoprost Approved, Investigational Phase 4 551-11-1 5283078

Interventional clinical trials:

(show top 50) (show all 844)
# Name Status NCT ID Phase Drugs
1 Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO Unknown status NCT00566761 Phase 4 bevacizumab and triamcinolone
2 Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study Unknown status NCT02651168 Phase 4
3 Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy Unknown status NCT01857544 Phase 4 Aflibercept
4 Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema Unknown status NCT02598869 Phase 4 Triamcinolone Acetonide
5 Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
6 The Endurance 1 Trial Unknown status NCT02297204 Phase 4 aflibercept 2.0 mg
7 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
8 POSTERIOR SUB-TENON'S Avastin Unknown status NCT00567372 Phase 4 bevacizumab (Sub-tenon´s injection)
9 To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema Unknown status NCT02462304 Phase 4 ranibizumab;Bevacizumab
10 Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration Unknown status NCT00716586 Phase 4 dorzolamide
11 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4 bevacizumab;bevacizumab
12 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
13 Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO) Unknown status NCT02432547 Phase 4 Aflibercept
14 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
15 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Unknown status NCT02522897 Phase 4 Ranibizumab
16 Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen Unknown status NCT02274259 Phase 4 Aflibercept;Ranibizumab
17 Changes in Macular Thickness After Patterns Scan Laser Unknown status NCT00563628 Phase 4
18 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
19 ALPI vs Medical Therapy Effects on Optic Nerve Structure & Function Unknown status NCT00485238 Phase 4 Intravenous acetazolamide
20 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
21 Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification Unknown status NCT01193504 Phase 4 Pred Forte;Lotemax
22 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
23 Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion Not yet recruiting NCT03709745 Phase 4 Aflibercept Injection [Eylea];Ranibizumab Injection [Lucentis]
24 Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema Completed NCT00682539 Phase 4 Bevacizumab (Avastin);Triamcinolone;Sham
25 Intravitreal Macugen for Ischaemic Diabetic Macular Oedema Completed NCT01175070 Phase 4 Intravitreal injection of pegaptanib sodium
26 Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab Recruiting NCT02665689 Phase 4 ranibizumab
27 Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema Completed NCT02646670 Phase 4 Ranibizumab;Aflibercept;Ranibizumab and Aflibercept;Aflibercept and ranibizumab
28 Fluocinolone Acetonide Insert (ILUVIEN®) for Diabetic Macular Edema (FAD) Study Withdrawn NCT02902744 Phase 4 ILUVIEN®
29 Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema Active, not recruiting NCT02471651 Phase 4 Dexamethasone intravitreal implant (0.7 mg);Intravitreal anti-VEGF injection
30 Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema. Recruiting NCT03458923 Phase 4 Diclofenac Sodium 0.1 ml containing 500µg;Ranibizumab 0.5 mg Solution for Injection
31 Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular Edema Recruiting NCT02441907 Phase 4 aflibercept
32 Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema Completed NCT02633852 Phase 4 Aflibercept
33 Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision Active, not recruiting NCT01795209 Phase 4 Ranibizumab
34 Macular Edema Nepafenac vs. Difluprednate Uveitis Trial Recruiting NCT01939691 Phase 4 Difluprednate;Nepafenac;Prednisolone acetate
35 Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study) Completed NCT01613716 Phase 4 Ozurdex
36 Laser (Selective Retina Therapy) and Drug Combined Intervention in Clinically Significant Diabetic Macular Edema Active, not recruiting NCT03759860 Phase 4
37 Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema Withdrawn NCT02055911 Phase 4 Ranibizumab
38 Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion Recruiting NCT03405376 Phase 4 Intravitreal aflibercept injection
39 A Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients Completed NCT02359526 Phase 4 IlUVIEN
40 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema Terminated NCT02684084 Phase 4 Ozurdex;Lucentis
41 Topical Nepafenac as Supplement for Diabetic Macular Edema Completed NCT02443012 Phase 4 Topical Gutt Nepafenac 0.1%
42 TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema Completed NCT01870440 Phase 4 Ozurdex Intravitreal Injection (0.7 mg)
43 Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab Recruiting NCT02559180 Phase 4 aflibercept
44 Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema Recruiting NCT02924987 Phase 4 Aflibercept Injection
45 Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study) Recruiting NCT02788877 Phase 4 aflibercept
46 Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa Active, not recruiting NCT02554747 Phase 4
47 Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema Completed NCT00737971 Phase 4 Bevacizumab intravitreal;Triamcinolone;Triamcinolone + Bevacizumab
48 Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema Completed NCT02036424 Phase 4 Ozurdex;Bevacizumab
49 Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment Completed NCT01257815 Phase 4 Ranibizumab
50 Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial (The Endurance 2 Trial) Completed NCT02368756 Phase 4 Aflibercept

Search NIH Clinical Center for Macular Dystrophy, Dominant Cystoid

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: macular edema

Genetic Tests for Macular Dystrophy, Dominant Cystoid

Anatomical Context for Macular Dystrophy, Dominant Cystoid

MalaCards organs/tissues related to Macular Dystrophy, Dominant Cystoid:

41
Eye, Endothelial, Retina, Bone, Myeloid, Bone Marrow, B Cells

Publications for Macular Dystrophy, Dominant Cystoid

Articles related to Macular Dystrophy, Dominant Cystoid:

(show top 50) (show all 773)
# Title Authors Year
1
Comparison of the Efficacy of Dexamethasone, Nepafenac, and Bromfenac for Preventing Pseudophakic Cystoid Macular Edema: an Open-label, Prospective, Randomized Controlled Trial. ( 29120255 )
2018
2
Is it melanoma-associated retinopathy or drug toxicity? Bilateral cystoid macular edema posing a diagnostic and therapeutic dilemma. ( 29780921 )
2018
3
Treatment of cystoid macular edema in homozygous twins with glutathione synthetase deficiency and retinal dystrophy. ( 29395598 )
2018
4
Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience. ( 29855706 )
2018
5
The role of cystoid macular edema as a marker in the progression of non-paraneoplastic autoimmune retinopathy. ( 30128606 )
2018
6
Cystoid macular edema after cataract surgery. ( 30473094 )
2018
7
Transient complete visual loss and subsequent cystoid macular edema after intracameral lidocaine injection following uneventful cataract surgery. ( 29988901 )
2018
8
Prevention of cystoid macular edema after cataract surgery in diabetic patients. ( 30055688 )
2018
9
Randomized controlled European multicenter trial on the prevention of cystoid macular edema after cataract surgery in diabetics: ESCRS PREMED Study Report 2. ( 30055692 )
2018
10
Prevention of cystoid macular edema after cataract surgery. ( 29778103 )
2018
11
European multicenter trial of the prevention of cystoid macular edema after cataract surgery in nondiabetics: ESCRS PREMED study report 1. ( 29778106 )
2018
12
Nonleaking cystoid macular edema in Cohen syndrome. ( 30144585 )
2018
13
OPTICAL COHERENCE TOMOGRAPHY BIOMARKERS TO DISTINGUISH DIABETIC MACULAR EDEMA FROM PSEUDOPHAKIC CYSTOID MACULAR EDEMA USING MACHINE LEARNING ALGORITHMS. ( 30312254 )
2018
14
Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib. ( 30188238 )
2018
15
Cystoid macular edema following selective laser trabeculoplasty in a patient with ocular hypertension. ( 30105491 )
2018
16
Bilateral cystoid macular edema misdiagnosed as pars planitis in a patient on sertraline therapy. ( 29984334 )
2018
17
Incidence and Risk Factors of Cystoid Macular Edema after Vitrectomy with Silicone Oil Tamponade for Retinal Detachment. ( 29022299 )
2018
18
Safety and long-term efficacy of repeated dexamethasone intravitreal implant for the treatment of cystoid macular edema secondary to retinal vein occlusion with and without a switch to anti-VEGF agents: a 3-year experience. ( 30069751 )
2018
19
Response to safety and long-term efficacy of repeated dexamethasone intravitreal implant for the treatment of cystoid macular edema secondary to retinal vein occlusion with and without a switch to anti-VEGF agents: a 3-year experience. ( 30084068 )
2018
20
Evaluation of the Effectiveness of Treatment with Dexamethasone Intravitreal Implant in Cystoid Macular Edema Secondary to Retinal Vein Occlusion. ( 30175123 )
2018
21
Treatment of cystoid macular edema secondary to retinitis pigmentosa: a systematic review. ( 28987613 )
2018
22
INTRAVENOUS IMMUNOGLOBULIN IN THE TREATMENT OF JUVENILE RETINITIS PIGMENTOSA-ASSOCIATED CYSTOID MACULAR EDEMA AND UVEITIS. ( 27828903 )
2018
23
INTRAVITREAL DEXAMETHASONE IMPLANT IN RETINITIS PIGMENTOSA-RELATED CYSTOID MACULAR EDEMA. ( 28221257 )
2018
24
Repeat Intravitreal Dexamethasone Implant for Refractory Cystoid Macular Edema in Syphilitic Uveitis. ( 29670789 )
2018
25
The Use of Topical Non-steroidal Anti-inflammatory Drugs for Uveitic Cystoid Macular Edema. ( 28080174 )
2018
26
Evaluation of pseudophakic cystoid macular edema using optical coherence tomography angiography. ( 29108396 )
2018
27
Indocyanine green angiography findings of cystoid macular edema secondary to paclitaxel therapy. ( 29270811 )
2018
28
Incidence of Cystoid Macular Edema After Descemet Membrane Endothelial Keratoplasty. ( 29298168 )
2018
29
RESPONSE OF INFLAMMATORY CYSTOID MACULAR EDEMA TO TREATMENT USING ORAL ACETAZOLAMIDE. ( 29346240 )
2018
30
Surgical cystotomy for refractory diabetic cystoid macular edema. ( 29406523 )
2018
31
Association of Postoperative Topical Prostaglandin Analog or Beta-Blocker Use and Incidence of Pseudophakic Cystoid Macular Edema. ( 29505438 )
2018
32
Topical interferon alpha 2b in the treatment of refractory pseudophakic cystoid macular edema. ( 29560479 )
2018
33
Preexisting epiretinal membrane is associated with pseudophakic cystoid macular edema. ( 29564551 )
2018
34
Difluprednate for the Treatment of Uveitic Cystoid Macular Edema. ( 29580977 )
2018
35
Prednisolone versus dexamethasone for prevention of pseudophakic cystoid macular edema. ( 29631823 )
2018
36
Resolution of cystoid macular edema following arginine-restricted diet and vitamin B6 supplementation in a case of gyrate atrophy. ( 29654911 )
2018
37
Metamorphopsia Score and Central Visual Field Outcomes in Diabetic Cystoid Macular Edema. ( 29744359 )
2018
38
Effect of topical dorzolamide therapy on cystoid macular edema in hydroxychloroquine retinopathy. ( 29784170 )
2018
39
Factors predicting response of pseudophakic cystoid macular edema to topical steroids and nepafenac. ( 29785993 )
2018
40
An unexpected complication in bilateral acute iris transillumination: Cystoid macular edema. ( 29786008 )
2018
41
Cystoid Macular Edema Due to Accidental Latanoprost Overdose After Uncomplicated Phacoemulsification. ( 29921209 )
2018
42
Reversible Cystoid Macular Edema Following Uneventful Microinvasive Kahook Dual Blade Goniotomy in a Pseudophakic Patient: A Case Report. ( 29965892 )
2018
43
BILATERAL INTRAVITREAL 0.19-MG FLUOCINOLONE ACETONIDE IMPLANT FOR PERSISTENT NONDIABETIC CYSTOID MACULAR EDEMA AFTER VITRECTOMY. ( 30015770 )
2018
44
CYSTOID MACULAR EDEMA IN THE SETTING OF PRIMARY VITREORETINAL LYMPHOMA. ( 30015778 )
2018
45
TOPICAL DORZOLAMIDE FOR CYSTOID MACULAR EDEMA IN BIETTI CRYSTALLINE RETINAL DYSTROPHY. ( 30028788 )
2018
46
Comparative study of the efficacy and safety of bromfenac, nepafenac and diclofenac sodium for the prevention of cystoid macular edema after phacoemulsification. ( 30046541 )
2018
47
Taxane induced Cystoid Macular Edema: Case Report and Integrated Pathogenic theory. ( 30156164 )
2018
48
PREOPERATIVE VITREORETINAL INTERFACE ABNORMALITIES ON SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY AS RISK FACTOR FOR PSEUDOPHAKIC CYSTOID MACULAR EDEMA AFTER PHACOEMULSIFICATION. ( 30157113 )
2018
49
Topical non-steroidal anti-inflammatory drugs for the treatment of cystoid macular edema post Descemet's stripping automated endothelial keratoplasty. ( 30255396 )
2018
50
EFFECTIVENESS OF EN BLOC REMOVAL OF FIBRINOGEN-RICH COMPONENT OF CYSTOID LESION FOR THE TREATMENT OF CYSTOID MACULAR EDEMA. ( 30334924 )
2018

Variations for Macular Dystrophy, Dominant Cystoid

ClinVar genetic disease variations for Macular Dystrophy, Dominant Cystoid:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 EYS NM_001142800.1(EYS): c.8519A> G (p.Glu2840Gly) single nucleotide variant Uncertain significance GRCh37 Chromosome 6, 64431408: 64431408
2 EYS NM_001142800.1(EYS): c.8519A> G (p.Glu2840Gly) single nucleotide variant Uncertain significance GRCh38 Chromosome 6, 63721512: 63721512

Expression for Macular Dystrophy, Dominant Cystoid

Search GEO for disease gene expression data for Macular Dystrophy, Dominant Cystoid.

Pathways for Macular Dystrophy, Dominant Cystoid

GO Terms for Macular Dystrophy, Dominant Cystoid

Cellular components related to Macular Dystrophy, Dominant Cystoid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 photoreceptor inner segment GO:0001917 8.62 CRB1 MAK

Biological processes related to Macular Dystrophy, Dominant Cystoid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 visual perception GO:0007601 9.43 BEST1 MFRP PDE6A
2 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.16 PRKCB VEGFA
3 retina development in camera-type eye GO:0060041 9.13 MFRP PDE6A SERPINF1
4 eye photoreceptor cell development GO:0042462 8.8 CRB1 MFRP VEGFA

Sources for Macular Dystrophy, Dominant Cystoid

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....